PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke
June 14th, 2018
13.6K views
Positron Emission Tomography (PET) imaging of translocator protein 18 kDa (TSPO) provides a non-invasive means to visualize the dynamic role of neuroinflammation in the development and progression of brain diseases. This protocol describes TSPO-PET and ex vivo autoradiography to detect neuroinflammation in a mouse model of ischemic stroke.
Overview
This article presents a protocol for using Positron Emission Tomography (PET) imaging to visualize neuroinflammation in a mouse model of ischemic stroke. The study highlights the advantages of PET imaging over traditional techniques, allowing for real-time observation of dynamic biological processes.
Key Study Components
Area of Science
- Neuroscience
- Imaging Techniques
- Neuroinflammation
Background
- Neuroinflammation is linked to various brain diseases, including stroke and Alzheimer's disease.
- Traditional techniques often rely on post-mortem analysis, limiting their ability to capture dynamic processes.
- PET imaging provides a non-invasive method to study these phenomena in living subjects.
- The translocator protein 18 kDa (TSPO) is a key target for imaging neuroinflammation.
Purpose of Study
- To quantify the spatial distribution and extent of neuroinflammation in a mouse model of ischemic stroke.
- To validate in vivo findings with ex vivo autoradiography.
- To demonstrate a step-by-step guide for using PET imaging in research.
Methods Used
- Injection of a specific PET radiotracer, DPA-713, known to bind to TSPO.
- Simultaneous imaging of multiple mice to enhance experimental efficiency.
- Use of a PET/CT scanner for dynamic imaging of neuroinflammation.
- Post-processing and analysis of PET data to visualize radioactivity uptake.
Main Results
- Successful visualization of neuroinflammation in the mouse model.
- Demonstrated the feasibility of simultaneous imaging of multiple subjects.
- Validated in vivo PET findings with ex vivo autoradiography.
- Provided a comprehensive protocol for researchers to replicate.
Conclusions
- PET imaging is a powerful tool for studying neuroinflammation in real-time.
- The protocol can streamline experiments and enhance data collection.
- Further research can expand the application of this technique to other brain diseases.
Frequently Asked Questions
What is TSPO?
TSPO stands for translocator protein 18 kDa, which is involved in neuroinflammation.
Why is PET imaging advantageous?
PET imaging allows for real-time observation of dynamic biological processes in living subjects.
How does this protocol improve efficiency?
By enabling simultaneous imaging of multiple mice, it increases throughput and reduces time spent on experiments.
What diseases can be studied using this technique?
This technique can be applied to study various brain diseases, including stroke, Alzheimer's, and multiple sclerosis.
What is the role of DPA-713?
DPA-713 is a radiotracer used in PET imaging to bind to TSPO and visualize neuroinflammation.
Can this protocol be adapted for other models?
Yes, while this study focuses on ischemic stroke, the protocol can be adapted for other neuroinflammatory models.
Executive Industry Relevance
Neuroinflammation is a key driver of pathological progression in ischemic stroke and other neurodegenerative diseases, yet its dynamic spatiotemporal evolution remains challenging to capture with static post-mortem methods. Non-invasive PET imaging using TSPO-targeted radiotracers like [11C]DPA-713 enables real-time, longitudinal quantification of microglial activation in living systems, providing critical mechanistic insights for target validation and therapeutic de-risking in neuroinflammatory pathways. This approach supports early discovery by delivering quantitative, translatable biomarkers that inform go/no-go decisions in preclinical pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of TSPO as a biomarker for microglial activation, supporting target hypothesis testing in neuroinflammatory pathways.
- Operational Value: Provides quantitative, longitudinal readouts of target engagement and biological response in vivo.
- Predictive Value: Facilitates mechanistic de-risking by linking TSPO expression to disease-relevant neuroinflammatory cascades in stroke models.
Screening & Assay Development
- Scientific Value: Generates standardized, reproducible PET-derived uptake metrics (e.g., ipsilateral vs. contralateral hemispheres) for comparative compound or genotype screening.
- Operational Value: Supports high-throughput experimental design through simultaneous multi-animal imaging, improving resource efficiency and data consistency.
- Assay Readiness: Establishes validated quantification protocols using manual ROI analysis and time-activity curves for downstream translational applications.
Translational & Preclinical Research
- Scientific Value: Enables correlation of in vivo PET signals with ex vivo autoradiography, strengthening target validation and biomarker reliability.
- Operational Value: Bridges discovery and preclinical workflows by providing non-invasive, repeatable monitoring of neuroinflammatory burden across disease progression.
- Translational Continuity: Supports biomarker qualification efforts by delivering quantifiable, disease-relevant neuroinflammatory readouts applicable to stroke and related CNS indications.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead optimization, offering a non-invasive imaging modality to monitor neuroinflammatory responses in disease-relevant preclinical models prior to compound advancement.
- Discovery Biology: Supports hypothesis-driven interrogation of TSPO-mediated neuroinflammation, enabling pathway clarification and target de-risking in stroke and neurodegenerative disease models.
- Screening: Delivers quantitative imaging endpoints (e.g., standardized uptake values) that allow side-by-side comparison of experimental conditions, genotypes, or therapeutic interventions.
- Analytics: Generates time-activity curves and ROI-based quantification outputs that enable statistical comparison of tracer uptake between ipsilateral and contralateral brain regions.
- Translational Research: Connects in vivo imaging findings to ex vivo validation, reinforcing biomarker reliability for neuroinflammatory pathways in stroke models.
- Enterprise Reuse: Establishes a reusable imaging platform applicable across multiple neuroinflammatory disease models, maximizing return on radiotracer and instrumentation investment.
Operational & Enterprise Impact
- Scientific Value: Provides predictive confidence in TSPO as a neuroinflammatory biomarker through longitudinal, quantifiable in vivo monitoring.
- Operational Value: Enhances throughput via simultaneous multi-subject imaging, reducing per-experiment cost and accelerating data acquisition.
- Strategic Value: Improves go/no-go decision-making by delivering objective, translatable neuroinflammatory readouts that reduce biological uncertainty in target validation.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on their ability to modulate TSPO-associated neuroinflammatory pathways in disease-relevant systems.
Implementation Considerations
- Requires expertise in PET/CT imaging, radiotracer handling, and small-animal anesthesia and cannulation techniques.
- Dependent on access to a PET/CT scanner, dose calibrator, and short-lived [11C]DPA-713 radiotracer with appropriate radiochemistry infrastructure.
- Necessitates standardized operating procedures for multi-animal setup, simultaneous injection, and post-scan radioactivity measurement to ensure reproducibility and radiation safety.
- Involves image analysis expertise for co-registration, ROI drawing, and quantification using arterial or reference tissue input methods.
- Limited by the short half-life of Carbon-11 (~20 minutes), requiring precise timing and on-site radiotracer synthesis or rapid delivery to maximize usable signal and minimize decay loss.
Biopharma FAQs
Why does TSPO quantification matter for target validation in stroke models?
TSPO quantification using [11C]DPA-713 PET enables longitudinal monitoring of microglial activation, providing a measurable biomarker to validate target engagement and pathway modulation in ischemic stroke models. This supports mechanistic de-risking by linking target inhibition to downstream neuroinflammatory changes in vivo.
How does simultaneous multi-mouse imaging improve efficiency in discovery pipelines?
Simultaneous imaging of up to four mice per radiotracer batch increases experimental throughput, reduces scan time per subject, and improves resource utilization in preclinical studies. This approach enhances reproducibility by minimizing inter-scan variability under identical tracer and instrument conditions.
What quantitative outputs enable comparative analysis of neuroinflammation?
Quantitative PET analysis generates time-activity curves and standardized uptake values from manually drawn ROIs in ipsilateral and contralateral hemispheres, allowing statistical comparison of [11C]DPA-713 uptake. These metrics support dose-response evaluation and comparative genotyping or treatment effect assessment in stroke models.
Why are replication requirements important for cross-functional collaboration?
Replication of PET imaging protocols ensures consistent quantification of neuroinflammatory signals across sites and teams, which is essential for multi-center preclinical studies and biomarker qualification efforts. Standardized ROI-based analysis and ex vivo validation via autoradiography strengthen data reliability for translational decision-making.
What statistical analysis capabilities are required before implementing TSPO-PET in discovery workflows?
Implementation requires capability to perform statistical comparison of ROI-derived uptake values (e.g., ipsilateral vs. contralateral) using appropriate tests such as t-tests or ANOVA to determine significant changes in TSPO binding. This enables objective evaluation of neuroinflammatory burden and treatment effects in disease models.
![Autoradiographic Measurements of [14C]-Iodoantipyrine in Rat Brain Following Central Post-Stroke Pain](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F53947.jpg%3Fv%3D2026-08-26T10%253A09%253A39.000Z&w=384&q=75)
